BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a biopharmaceutical company developing medicines in neuroscience, with its wholly owned subsidiary, OnkosXcel Therapeutics, focused on immuno-oncology. Its lead neuroscience product is IGALMI®, an FDA-approved sublingual dexmedetomidine film for the acute treatment of agitation associated… From the company’s description.
Over the twelve months to Jun 30, 2026, BioXcel Therapeutics, Inc. reported revenue of $0.74M, down 14.5% from a year earlier, and a net loss of $70.86M. Operations used $50.90M in cash. In fiscal 2025, it reported revenue of $0.64M, down 71.7% from fiscal 2024, and a net loss of $69.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioXcel Therapeutics, Inc. does
In the company’s own words
BioXcel Therapeutics, Inc. is a biopharmaceutical company developing medicines in neuroscience, with its wholly owned subsidiary, OnkosXcel Therapeutics, focused on immuno-oncology. Its lead neuroscience product is IGALMI®, an FDA-approved sublingual dexmedetomidine film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults; the company is also developing BXCL501 for additional agitation settings, including at-home use and Alzheimer’s-related dementia. OnkosXcel’s lead candidate, BXCL701, is an investigational oral immune activator being studied for aggressive prostate and pancreatic cancers and other tumors. The company uses artificial intelligence and machine-learning methods to identify new uses for existing drugs and clinical candidates, although investment in its AI platform has been reduced. IGALMI is supplied through existing distribution channels, with limited commercial resources, and the company is seeking potential commercial partners. Net revenue from IGALMI product sales was $0.6 million in 2025. Its website is www.bioxceltherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1720893
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioXcel Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioXcel Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioXcel Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioXcel Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioXcel Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”